Incretin Atlas › Trials › HDM1005 phase 2 (T2D)
HDM1005 phase 2 (T2D)
HDM1005 · t2d
Design
- Molecule(s)
- HDM1005
- Population
- t2d
- Phase
- 2
- Participants
- 220
- Duration
- 20 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDM1005 3.0 mg | t2d china | 20 | 220 | −5.9 % vs −0.2 % Δ −5.7 pp | — | −2.6 vs −0.6 | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- HDM1005 3.0 mg · weight_eff · Abstract, Results
Dose-dependent body weight reductions were observed (LSM percentage change: -2.53%, -5.10%, -5.45%, -5.89% vs - 0.17% for placebo)
- HDM1005 3.0 mg · hba1c · Abstract, Results
the least squares mean (LSM) changes in HbA1c were -1.95%, -2.40%, -2.45%, and -2.57% for HDM1005 0.5, 1.0, 2.0, and 3.0 mg groups
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HDM1005 phase 2 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1005-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.